# US 8,772,353 B2 · Method for enhancing the bioavalability of ospemifene > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,772,353 B2 - Document ID: US8772353B2 - Status: Granted - Kind: B2 - Application number: 13/904,818 - Filed: 2013-05-29 - Published: 2013-12-05 - Granted: 2014-07-08 - Earliest claimed: 2004-02-13 - Assignees: Hormos Medical Corporation - Applicants: Hormos Medical Ltd. - Inventors: Markku Anttila - Web page: https://patentgrep.com/patent/US8772353B2 ## CPC - A61K 31/085: having an ether linkage to aromatic ring nuclear carbon - A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 31/075: Ethers or acetals - A61P 5/30: Oestrogens - A61P 13/00: Drugs for disorders of the urinary system - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 15/02: for disorders of the vagina - A61P 17/00: Drugs for dermatological disorders - A61P 19/10: for osteoporosis - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION ## Abstract This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food. ## Claims ### Claim 1 A method of treating sexual dysfunction comprising orally administering a therapeutically effective amount of ospemifene or a pharmaceutically acceptable salt thereof to a patient in need thereof in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof. ### Claim 2 (depends on 1) The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake. ### Claim 3 (depends on 2) The method according to claim 2 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is in the range defined to begin at a time point during the food intake and to end 1 hour after the food intake was started. ### Claim 4 (depends on 3) The method according to claim 3 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is no later than 0.5 hours after starting the food intake. ### Claim 5 (depends on 2) The method according to claim 2 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. ### Claim 6 (depends on 5) The method according to claim 5 wherein the dosage amount is 60 mg. ### Claim 7 (depends on 2) The method of claim 2 wherein said patient is a perimenopausal or postmenopausal woman. ### Claim 8 (depends on 1) The method according to claim 1 wherein said sexual dysfunction is dyspareunia. ### Claim 9 (depends on 8) The method according to claim 8 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. ### Claim 10 (depends on 9) The method according to claim 9 wherein the dosage amount is 60 mg. ### Claim 11 (depends on 10) The method of claim 10 where said patient is a perimenopausal or postmenopausal woman. ### Claim 12 (depends on 1) The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. ### Claim 13 (depends on 12) The method according to claim 12 wherein the dosage amount is 60 mg. ### Claim 14 (depends on 1) The method of claim 1 wherein said patient is a perimenopausal or a postmenopausal woman. ### Claim 15 A method of treating sexual dysfunction comprising orally administering a therapeutically effective amount of ospemifene to a patient in need thereof in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof. ### Claim 16 (depends on 15) The method according to claim 15, wherein the ospemifene is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake. ### Claim 17 (depends on 15) The method according to claim 15, wherein said sexual dysfunction is dyspareunia. ### Claim 18 (depends on 17) The method according to claim 17, wherein the dosage amount is 60 mg. ### Claim 19 (depends on 17) The method of claim 17, wherein said patient is a perimenopausal or a postmenopausal woman.